Patients with mantle cell lymphoma (MCL) may be able to undergo induction treatment with a combination of ibrutinib (Imbruvica, Pharmacyclics) and rituximab (Rituxan, Genentech), without requiring concomitant chemoimmunotherapy. The preliminary trial results, presented at the 2016 annual meeting of the American Society of Hematology (abstract 147), suggest that the two-drug combination alone does not compromise efficacy in the absence of chemoimmunotherapy, and may be associated with a better
JANUARY 5, 2017